Introduction
P eripheral arterial disease (PAD), which is caused by atherosclerotic occlusion of the arteries to the legs, is an important manifestation of systemic atherosclerosis. 1) The most common symptomatic manifestation of mild to moderate PAD is intermittent claudication. These patients have reduced walking capacity that leads to physical limitations and disability that can reduce their quality of life.
The ankle-brachial index (ABI) is widely used to diagnose PAD noninvasively, 2) whereas treadmill testing is the objective "gold standard" to estimate the functional limitation of claudication, assessing pain-free and maximal walking distance or times. 3) However, this laboratory test does not necessarily reflect walking ability during daily activities and may not be practicable for the general practitioner. 4) There is thus a need for an appropriate measurement with which to estimate the degree of physical functioning in social life. One such measurement is the Walking Impairment Questionnaire (WIQ), which quantifies the ability to walk on the basis of the severity of pain, walking distance, walking speed, and stairclimbing ability and characterizes the symptoms that limit walking 5) . The WIQ distance score correlates well with peak treadmill walking time ( r = 0.68). 4) The WIQ has been translated into a number of languages and has recently been translated into Japanese and culturally adapted. We have previously demonstrated the reliability and validity of the Japanese version, showing that the WIQ distance score correlates with peak treadmill walking time ( r = 0.69), 6) a finding compatible with the original report on this questionnaire.
Antiplatelet therapy is recommended to relieve claudication associated with PAD. 2, 3) Among antiplatelet agents, sarpogrelate, a selective 5-HT 2A receptor antagonist, has been approved for PAD and is in wide use in Japan, China, and the Republic of Korea. 7) It inhibits serotonin-induced platelet aggregation, vasoconstriction, and vascular smooth muscle cell proliferation, [8] [9] [10] which is mediated by 5-HT 2A receptors, and consequently reduces the ischemic symptoms associated with PAD. However, the effects of sarpogrelate on exercise performance and functional status have not been evaluated systematically in Japanese patients. We therefore investigated the efficacy of sarpogrelate in improving walking ability using the Japanese version of the WIQ in patients with intermittent claudication. In addition, the safety of sarpogrelate was evaluated. We also examined the correlation between the ABI and the WIQ scores, as a few studies demonstrate significant correlations, whereas others show minimal if any correlation, and we wished to clarify the question.
Methods

Patient Selection
A total of 586 patients were investigated over a period of 1 year and 7 months, from May 2005 to November 2006, at 80 institutions across Japan (see Appendix for list). The inclusion criterion was stable symptoms of intermittent claudication. Patients classified as Fontaine stage III or IV were to be included if they were able to walk. In addition, patients for whom conservative therapy was indicated were included. All patients were to be given 300 mg of open-labeled sarpogrelate per day, and the dosage was increased or reduced as needed according to the patient's age and symptoms. The duration of treatment was to be set as at least 24 weeks, in accordance with the recommendation of the TransAtlantic Inter-Society Consensus (TASC) for clinical trials.
3) Patients were allowed to take other antiplatelet drugs.
The following subjects were excluded: 1) those without functional limitation by claudication (Fontaine stage I); 2) those with contraindications to the use of sarpogrelate; i.e., hemorrhagic tendencies or confirmed or possible pregnancy; and 3) those considered inappropriate for the study by their physicians. Among the subjects initially valid for efficacy analysis, patients who had undergone a revascularization procedure were excluded. Informed consent was obtained from each patient before participation.
Clinical Outcome Primary Outcome
To evaluate walking function, the Japanese version of the WIQ was administered by interview by a physician before treatment with sarpogrelate and at follow-up. The WIQ consists of four questions. Question 1 is divided into two parts: the first assesses the degree of pain specific to claudication, while the second is designed for differential diagnosis of other diseases that could limit ambulation. Question 2 measures the difficulty walking a given distance on level ground, Question 3 measures the ability to walk at various speeds for 100 meters, and Question 4 measures the difficulty in climbing stairs without stopping. Each individual response is multiplied by its respective weight to create an individual score. All individual scores for a question are summed and then divided by the maximum possible score to obtain the score for analysis. A score of 0 to 100 is used to measure each domain, with a score of 0 representing inability to perform because of severe claudication and 100 representing no difficulty with performance.
Secondary Outcome
Resting ABI measurements were made at baseline and follow-up using automated devices, the Form ® (Omron Colin, Tokyo, Japan) and the VaSera ® (Fukuda Denshi, Tokyo, Japan). The brachial-ankle pulse wave velocity (baPWV) and the cardio-ankle vascular index (CAVI) were determined simultaneously with these instruments.
Examination of Adverse Reactions
Any medically unfavorable or unintended signs and symptoms observed during or after administration of sarpogrelate were considered adverse events, and the presence or absence, type, date, seriousness, outcome, causal relation to this agent, factors suspected other than this agent, course from the onset of the event to outcome, and comments of the physician in charge were recorded. All drug-related adverse events were described as adverse drug reactions, and adverse events for which a causal relation to the agent could not be ruled out were considered adverse reactions. Blood pressure and pulse rate were also measured for assessment of safety.
Statistical Analysis
For all data collection, the Electronic Data Capture system was employed, which links with a server via the Internet from computer terminals at each study site for data input and transmission. The primary efficacy analysis was performed on the full analysis set (FAS), which was a population corresponding as much as possible to the intention to treat population. Patients who received sarpogrelate more than 24 weeks were defined as the per-protocol set (PPS) and used for secondary analysis. The lowest leg ABI measurement was used in the analysis.
Means and standard deviations were calculated for efficacy measurements at baseline and follow-up. Changes from baseline were analyzed statistically by the Wilcoxon signed-rank test. Significance was set at p < 0.05. Pearson correlation coefficients between resting ABI and WIQ scores were calculated. All statistical calculations were performed with SAS version 9.1 (SAS Institute, NC, Cary).
Results
Patient Data
A total of 597 patients were enrolled, and 586 patients were investigated, of whom 27 were excluded, most often for failure to complete the follow-up. A total of 559 patients were evaluable for the safety analysis. A total of 140 patients were excluded for the efficacy evaluation, 88 because of missing data or evaluation at an inappropriate date and 52 because they underwent revascularization procedures. Therefore, 419 patients were included in the FAS, and 354 were included in the PPS, excluded 65 patients because they were treated for less than full 24 weeks. Patient characteristics of the FAS are shown in Table 1 .
Efficacy
In the FAS, all subscales of WIQ score demonstrated significant improvement with sarpogrelate treatment ( Table 2 ). The pattern of responses was similar to the PPS. All these changes were significant at p < 0.0001. The mean follow-up was 27.7 Ȁ 10.1 weeks in the FAS and 30.5 Ȁ 8.1 weeks in the PPS.
Hemodynamic parameters in the FAS are shown in Table 3 . The resting ABI increased significantly ( p < 0.0001), whereas the baPWV in the diseased and healthy legs revealed no significant change. The sample size of CAVI was 26 because only a few institutions had the VaSera ® available. 
Safety
The incidence of adverse reactions in the 559 patients was 4.83% (27 patients) ( Table 4 ). The primary adverse reactions were gastrointestinal disorders such as abdominal discomfort and constipation (10 patients; 1.79%) and skin and appendage disorders such as rash (8 patients; 1.43%). Only one serious adverse reaction was observed. This was a subarachnoid hemorrhage in a woman in her 80s who had known cerebrovascular disease and sustained a rupture of an intracranial aneurysm. Although the physician in charge had suggested that this patient had a right middle cerebral aneurysm, considering her age, follow-up had been performed without surgery. The physician in charge believed that the aneurysm rupture was more likely to have been attributable to the natural course of this lesion than to the drug, and the causal relation of this adverse reaction to the drug could not be determined.
Bleeding-related adverse reactions were seen in three other patients. There were no adverse reactions associated with platelet/coagulation disorders; but one case each of intraoral bleeding, retinal hemorrhage, and subcutaneous bleeding, as well as the above-noted subarachnoid hemorrhage, were recorded. These three adverse reactions were not serious.
The systolic and diastolic blood pressure was 140.6 Ȁ 20.0 and 76.9 Ȁ 11.7 mmHg, respectively, at baseline and 136.7 Ȁ 18.2 and 75.7 Ȁ 10.8 mmHg at follow-up ( p < 0.0001 and p = 0.0141, respectively) in 461 patients. The pulse rate was 72.2 Ȁ 11.6 beat/min at baseline and 71.4 Ȁ 11.0 beat/min at follow-up ( p = 0.1350) in 436 patients.
ABI and WIQ
The relation between the hemodynamic PAD severity, 21 9.2 Ȁ 2. ABI, and each subscale of the WIQ is shown in Table 5 . The baseline ABI was modestly but significantly correlated with each subscale of the WIQ. The correlation coefficient of the ABI with the WIQ pain score was r = 0.32 ( p < 0.0001), which was the highest among the subscales. The correlation coefficient of ABI with walking distance score was 0.24 ( p < 0.0001). Furthermore, we evaluate the correlation between changes in ABI and each WIQ score from baseline to follow-up. We found the correlation coefficient was lower than that at baseline ( Table 5 ).
Discussion
Although the traditional objectives of intervention in patients with PAD have been symptomatic relief and limb salvage, in recent years, functional outcome has been recognized as an important endpoint, 11, 12) and the significance of treatment has come to lie in improving the patient's health-related quality of life. The TASC recommends that disease-specific functional health measurement be an integral part of outcome measurement in clinical trials in patients with intermittent claudication.
The WIQ is a reliable, validated, disease-specific questionnaire; and a number of studies have demonstrated its usefulness in assessing physical function in PAD patients. [13] [14] [15] Indeed, we also found the WIQ to be a useful instrument to quantify ambulatory function of daily life in clinical settings, taking only a short time without unnecessarily burdening the patient or the clinical staff.
Serotonin (5-hydroxytryptamine, 5-HT), an endogenous monoamine, has a variety of physiological effects. It is stored in circulating platelets, and once platelets are activated at sites of endothelial injury, serotonin is released to play an important role in thrombotic occlusion. 16) In atherothrombotic disease such as PAD, plasma serotonin concentrations are increased substantially. 17) To date, 14 distinct subtypes of serotonin receptors have been identified by molecular techniques.
18) The 5-HT 2A receptors are located mainly on platelets and vascular smooth muscle cells and mediate a variety of actions, such as platelet aggregation and vascular smooth muscle contraction and proliferation at sites of atherosclerotic lesions, 19) which contribute to circulatory disorders and the progression of arteriosclerosis. Thus, 5-HT 2A receptor antagonists are expected to inhibit these serotonin responses and ameliorate ischemic symptoms by improving hemodynamics.
In the TASC II, the 5-HT 2A receptor antagonist naftidrofuryl as well as cilostazol were recommended for pharmacotherapy of claudication (grade A). A number of trials in patients with PAD have demonstrated improvement of treadmill performance and quality of life with the use of naftidrofuryl, with a good safety profile. [20] [21] [22] Naftidrofuryl has been available in several European countries for more than 20 years but is not marketed in Asian countries. Sarpogrelate has been used in Japan to treat patients with PAD since 1993. A randomized, double-blind, placebo-controlled study of the drug was conducted in European countries, the results of which confirmed that the increase in absolute claudication distance (ACD) after 24 weeks of administration did not reach a statistically sig- nificant difference from placebo. However, responder analysis (defined as ≥ 50% improvement in ACD) revealed a statistically significant difference compared with placebo, indicating promising results without safety concerns, 23) as described in TASC II. We speculate that the differences in the results of the present study and those of the European study have the following origin. In the European study, the ACD was reported for the group taking sarpogrelate 200mg bid as increasing by 42% from baseline over 24 weeks, with a 31% increase in patients taking the placebo. The remarkable effect observed in the placebo group was thought to be attributable to improved exercise capacity as the result of repeated examinations, and it was not statistically significant to the sarpogrelate group. In the current study, sarpogrelate increased the walking distance score by 40% from baseline, and although the characteristics of the patients, study design, and endpoint are different from those in the European study, the improvement seems to be similar to that observed in the earlier study. In the present study, the baseline scores of WIQ were lower than those reported for non-PAD (distance 79.0 Ȁ 31.4; speed 63.9 Ȁ 29.5; stair-climbing 70.1 Ȁ 30.0), 24) which suggests that the study included functionally limited patients. The fact that each score of the WIQ was increased significantly by sarpogrelate treatment suggests that the agent enhances ambulatory function in daily life in patients with intermittent claudication.
In addition to the mechanism discussed above, increasing collateral circulation might be another explanation for the improvement of walking ability. Collateral vessels are more sensitive to vasoconstriction in response to serotonin than are normal vessels because of greater 5-HT 2A receptor-mediated sensitivity. A previous clinical trial demonstrated that sarpogrelate augments flow reserve of the collateral circulation and improves exercise capacity in anginal patients, 25) and this could be the mechanism for better physical function in PAD.
It has been reported that cilostazol improved the walking distance subscale significantly more than did placebo in five of six trials conducted in the US. However, the scores were not presented. Money et al. reported that after 16 weeks of cilostazol treatment, the walking speed score improved by 20%, with a significant increase in absolute walking distance on treadmill testing. 26) In the present study, sarpogrelate increased the walking speed score by 37% from the baseline; this difference might have resulted from the duration of treatment and the severity of the disease. NM-702, a novel phosphodiesterase inhibitor, increased the score for walking distance by 8.4 Ȁ 20.2 after treatment for 24 weeks, and showed a significant difference from placebo (1.6 Ȁ 16.6).
27) Our results are similar to those with these other agents, although a randomized controlled trial must be performed to reach clear conclusions.
With reference to safety, there was a decrease in blood pressure at follow-up in patients taking sarpogrelate, but these changes were not clinically significant. Further, no blood pressure-related adverse event such as orthostatic hypotension or dizziness was reported. The incidence of adverse reactions in our study was 4.83%, which is not significantly higher than the combined incidence in the clinical trials and postmarketing surveillance (2.23%; 107/4,807). 28) There were no clinically significant safety concerns clearly linked to the drug, confirming the good tolerability of this agent. Disease severity can be assessed noninvasively by ABI. However, the relation between ABI and functional status is complex and contradictory. 5) It has been reported that no significant correlation exists between change in resting ABI and improvement in WIQ walking distance in patients who have undergone bypass surgery.
14) The relation between these parameters might be affected by a number of psychological and clinical factors, such as age, disease severity, concomitant disease, and the ability to adjust to disability. Feinglass et al. reported that ABI correlated significantly with WIQ walking distance score in 555 patients ( r = 0.18; p < 0.001). 29) Myers et al. presented a correlation coefficient of r = 0.29 between the same parameters ( p < 0.05) in 48 patients. 30) In the present study, the correlation between the baseline of ABI and the WIQ pain score and walking distance score in 329 patients is consistent with previous reports ( r = 0.32; p < 0.0001 and r = 0.24; p < 0.0001, respectively). The present study showed a smaller correlation between the changes in ABI and each WIQ score, and this may be attributable to the fact that exercise or drug regimens does not necessarily affect the ABI.
3) In fact, ABI increased only 0.05 from the baseline in our study.
Study limitations
There are a few limitations to our findings. (1) The sarpogrelate monotherapy group was stratified for analysis. As a result, we confirmed significant improvement pre-to post-treatment in WIQ score (data not shown), and the results may thus reflect improvement by sarpogrelate. However, this was an observational study, and to clarify the effects of sarpogrelate, it will be essential to conduct a randomized controlled trial. (2) The primary endpoint was the efficacy of sarpogrelate, as reflected in the new Japanese version of WIQ. No treadmill testing was planned to evaluate the walking distance, partly because most medical institutions, including general practitioners' offices, do not possess the equipment necessary to conduct this test. Such testing may be necessary in the future to elucidate the efficacy of sarpogrelate. (3) Although the WIQ has been validated for interviewer administration, the physicians in charge rather than a third party interviewed the patients, so the method of administration might have caused bias and affected the results.
Conclusion
We have for the first time demonstrated, using the newly developed Japanese version of WIQ, that sarpogrelate, a 5-HT 2A receptor antagonist, may improve walking ability in daily life in patients who have intermittent claudication. The drug has a good safety profile.
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